SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
NexStar Pharm(NXTR)
An SI Board Since December 1996
Posts SubjectMarks Bans Symbol
328 5 0 NXTR
Emcee:  Miljenko Zuanic Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
203 Miljenko, The abstracts don't seem to be available, but you can download aBiomaven-9/23/1997
202 Peter: Are the ICAAC abstracts available on-line? If yes, what is the link? TMiljenko Zuanic-9/22/1997
201 Peter: Thanks for link. In my post #194 I wrote one incorrect presumption (pMiljenko Zuanic-9/20/1997
200 Miljenko: Here's an abstract about the Mikasome Phase I trial - basically Biomaven-9/19/1997
199 Steven: I do follow cancer field generally (with focus on new and improved theMiljenko Zuanic-9/19/1997
198 Hong-Lee, NXTR is going to take a charge in 97Q3, which will include an upfronSteven Yang-9/19/1997
197 MZ, Glad to know that you are comfortably in black in your NXTR investment. ISteven Yang-9/19/1997
196 Steven, Thanks for your info. You have not taken into the consideration the roHong-Lee Yu-9/18/1997
195 I agree with your post. I was not looking for ANY effectivness data. I was focuBill Tomko-9/18/1997
194 Hi Bill: News was in line for phase I trials. Side effects profile and pharmacMiljenko Zuanic-9/17/1997
193 Steven: My average NXTR price is at ~12. SBC debenture financing or any other Miljenko Zuanic-9/17/1997
192 Hong-Lee, The rational for NXTR to be in black in 97Q4 is based on: a) reducedSteven Yang-9/17/1997
191 MZ, I too feel that NXTR is undervalued, given its approved products, its techSteven Yang-9/17/1997
190 TA indications: etrade.stkwtch.comDon Cheng-9/17/1997
189 I don't understand your coment RE: "no efficency Data" Please claBill Tomko-9/17/1997
188 Mikasome: prnewswire.com No efficiency data! Hmm... mzMiljenko Zuanic-9/16/1997
187 Peter: Abstract from Nature: nature.com News sound OK. I do not know how exacMiljenko Zuanic-9/11/1997
186 Miljenko, Could you comment on the following release: biz.yahoo.com It referBiomaven-9/11/1997
185 Steven, I am the shareholder of NXTR for over a year now. In your previous poHong-Lee Yu-9/7/1997
184 Baird: One more thing is interesting to noted: During Aug. NXTR short interesMiljenko Zuanic-9/7/1997
183 Baird: >> 2 officers sold 11,610 shares between 8/1 and 8/20 @$8.12 ($94Miljenko Zuanic-9/7/1997
182 Insider Trader reports some insider selling in NXTR: 2 officers sold 11,610 shCzechsinthemail-9/6/1997
181 Steven: Be patience. SBC W. didn't invest in NXTR debentures because of Miljenko Zuanic-9/5/1997
180 To all NXTR investors: I have been long on NXTR, and feel strongly that NXTR iSteven Yang-9/4/1997
179 Baird: NexStar web site: nexstar.com SELEX for diagnostic: nexstar.com I tMiljenko Zuanic-8/27/1997
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News